Regeneron Pharmaceuticals (NASDAQ:REGN) Lowered to Buy at StockNews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by stock analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday.

REGN has been the topic of several other reports. Truist Financial reiterated a “buy” rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Royal Bank of Canada reiterated an “outperform” rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. BMO Capital Markets lifted their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. Morgan Stanley lifted their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. Finally, Bank of America lifted their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $976.41.

Regeneron Pharmaceuticals Stock Up 0.3 %

REGN opened at $896.82 on Friday. Regeneron Pharmaceuticals has a 12 month low of $684.80 and a 12 month high of $998.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The stock has a market cap of $98.43 billion, a P/E ratio of 25.81, a P/E/G ratio of 2.60 and a beta of 0.11. The stock’s 50 day moving average price is $953.01 and its 200 day moving average price is $891.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same period last year, the firm earned $10.96 EPS. The firm’s revenue was up .6% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals will post 38.59 earnings per share for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the sale, the executive vice president now directly owns 13,789 shares in the company, valued at approximately $12,888,716.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Joseph L. Goldstein sold 2,707 shares of the firm’s stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the transaction, the director now directly owns 6,382 shares of the company’s stock, valued at $6,062,900. The disclosure for this sale can be found here. Insiders have sold 13,729 shares of company stock worth $13,124,641 in the last ninety days. Insiders own 8.83% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Maryland State Retirement & Pension System lifted its holdings in Regeneron Pharmaceuticals by 0.9% during the 1st quarter. Maryland State Retirement & Pension System now owns 8,048 shares of the biopharmaceutical company’s stock valued at $7,306,000 after purchasing an additional 68 shares during the last quarter. Mezzasalma Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Mezzasalma Advisors LLC now owns 2,533 shares of the biopharmaceutical company’s stock valued at $2,438,000 after purchasing an additional 33 shares during the last quarter. Marshall Financial Group LLC lifted its holdings in Regeneron Pharmaceuticals by 9.7% during the 1st quarter. Marshall Financial Group LLC now owns 1,022 shares of the biopharmaceutical company’s stock valued at $984,000 after purchasing an additional 90 shares during the last quarter. FCG Investment Co lifted its holdings in Regeneron Pharmaceuticals by 4.3% during the 1st quarter. FCG Investment Co now owns 754 shares of the biopharmaceutical company’s stock valued at $726,000 after purchasing an additional 31 shares during the last quarter. Finally, Retirement Guys Formula LLC bought a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $1,148,000. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.